CORCEPT THERAPEUTICS INC's ticker is CORT and the CUSIP is 218352102. A total of 211 filers reported holding CORCEPT THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 2.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $6,477,011 | +29.0% | 199,354 | 0.0% | 0.00% | 0.0% |
Q1 2024 | $5,021,727 | -36.8% | 199,354 | -18.5% | 0.00% | -33.3% |
Q4 2023 | $7,941,198 | +63.6% | 244,495 | +37.3% | 0.00% | +50.0% |
Q3 2023 | $4,853,016 | +16.5% | 178,125 | -4.9% | 0.00% | 0.0% |
Q2 2023 | $4,165,734 | +0.5% | 187,224 | -2.2% | 0.00% | 0.0% |
Q1 2023 | $4,146,244 | -0.7% | 191,424 | -6.9% | 0.00% | 0.0% |
Q4 2022 | $4,175,005 | -20.7% | 205,564 | +0.1% | 0.00% | -33.3% |
Q3 2022 | $5,267,000 | +7.9% | 205,408 | +0.0% | 0.00% | +50.0% |
Q2 2022 | $4,883,000 | +3.3% | 205,329 | -2.2% | 0.00% | 0.0% |
Q1 2022 | $4,728,000 | +1.6% | 209,955 | -10.6% | 0.00% | 0.0% |
Q4 2021 | $4,652,000 | -31.4% | 234,941 | -31.9% | 0.00% | -33.3% |
Q3 2021 | $6,786,000 | +27.9% | 344,804 | +43.0% | 0.00% | +50.0% |
Q2 2021 | $5,306,000 | -9.9% | 241,194 | -2.6% | 0.00% | -33.3% |
Q1 2021 | $5,889,000 | -8.5% | 247,534 | +0.6% | 0.00% | 0.0% |
Q4 2020 | $6,439,000 | +50.3% | 246,134 | 0.0% | 0.00% | +50.0% |
Q3 2020 | $4,284,000 | -6.7% | 246,134 | -9.9% | 0.00% | -33.3% |
Q2 2020 | $4,593,000 | +42.0% | 273,040 | +0.4% | 0.00% | +50.0% |
Q1 2020 | $3,234,000 | -1.0% | 272,020 | +0.7% | 0.00% | 0.0% |
Q4 2019 | $3,268,000 | -16.7% | 270,070 | -2.7% | 0.00% | 0.0% |
Q3 2019 | $3,924,000 | +16.6% | 277,620 | -8.0% | 0.00% | 0.0% |
Q2 2019 | $3,365,000 | +10.5% | 301,770 | +16.4% | 0.00% | 0.0% |
Q1 2019 | $3,044,000 | -12.1% | 259,270 | 0.0% | 0.00% | -33.3% |
Q4 2018 | $3,464,000 | -4.7% | 259,270 | 0.0% | 0.00% | +50.0% |
Q3 2018 | $3,635,000 | -54.6% | 259,270 | -49.1% | 0.00% | -66.7% |
Q2 2018 | $8,006,000 | +118.7% | 509,270 | +128.9% | 0.01% | +100.0% |
Q1 2018 | $3,660,000 | -18.2% | 222,510 | -10.2% | 0.00% | 0.0% |
Q4 2017 | $4,473,000 | -11.0% | 247,690 | -4.9% | 0.00% | -25.0% |
Q3 2017 | $5,025,000 | +42.6% | 260,360 | -12.8% | 0.00% | +33.3% |
Q2 2017 | $3,523,000 | -7.8% | 298,540 | -14.4% | 0.00% | 0.0% |
Q1 2017 | $3,822,000 | +30.7% | 348,680 | -13.5% | 0.00% | +50.0% |
Q4 2016 | $2,925,000 | +12.4% | 402,940 | +0.7% | 0.00% | 0.0% |
Q3 2016 | $2,602,000 | +113.5% | 400,240 | +79.2% | 0.00% | +100.0% |
Q2 2016 | $1,219,000 | +251.3% | 223,320 | +201.0% | 0.00% | – |
Q1 2016 | $347,000 | -6.2% | 74,200 | 0.0% | 0.00% | – |
Q4 2015 | $370,000 | +28.5% | 74,200 | -3.3% | 0.00% | – |
Q3 2015 | $288,000 | -38.7% | 76,700 | -1.9% | 0.00% | – |
Q2 2015 | $470,000 | +20.2% | 78,200 | +12.0% | 0.00% | – |
Q1 2015 | $391,000 | +88.9% | 69,800 | +1.0% | 0.00% | – |
Q4 2014 | $207,000 | +11.9% | 69,100 | 0.0% | 0.00% | – |
Q3 2014 | $185,000 | -4.1% | 69,100 | 0.0% | 0.00% | – |
Q2 2014 | $193,000 | -43.1% | 69,100 | -11.1% | 0.00% | – |
Q1 2014 | $339,000 | +29.4% | 77,700 | -4.7% | 0.00% | – |
Q4 2013 | $262,000 | +56.9% | 81,500 | -22.3% | 0.00% | – |
Q3 2013 | $167,000 | -10.7% | 104,900 | -3.0% | 0.00% | – |
Q2 2013 | $187,000 | – | 108,107 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
INGALLS & SNYDER LLC | 8,303,147 | $209,156 | 9.24% |
TANAKA CAPITAL MANAGEMENT INC | 90,876 | $2,289 | 5.64% |
Checkpoint Capital L.P. | 273,776 | $6,896,417 | 4.61% |
Novo Holdings A/S | 2,411,362 | $60,742,209 | 4.19% |
Ikarian Capital, LLC | 994,500 | $25,051,455 | 2.75% |
Parallel Advisors, LLC | 3,815,677 | $96,116,904 | 2.60% |
Quantedge Capital Pte Ltd | 180,642 | $4,550,372 | 1.91% |
Kynam Capital Management, LP | 585,900 | $14,758,821 | 1.54% |
S&T BANK/PA | 290,487 | $7,317 | 1.40% |
AlphaCentric Advisors LLC | 85,000 | $2,141,150 | 1.29% |